NO20001002L - Oxo-substituerte forbindelser, fremgangsmõte for fremstilling, og sammensetninger og metoder for hemming av PARP aktiviteter - Google Patents
Oxo-substituerte forbindelser, fremgangsmõte for fremstilling, og sammensetninger og metoder for hemming av PARP aktiviteterInfo
- Publication number
- NO20001002L NO20001002L NO20001002A NO20001002A NO20001002L NO 20001002 L NO20001002 L NO 20001002L NO 20001002 A NO20001002 A NO 20001002A NO 20001002 A NO20001002 A NO 20001002A NO 20001002 L NO20001002 L NO 20001002L
- Authority
- NO
- Norway
- Prior art keywords
- methods
- ring
- compounds
- independently hydrogen
- alkyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000000203 mixture Substances 0.000 title abstract 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 239000001257 hydrogen Substances 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002837 carbocyclic group Chemical group 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- -1 hydrate Chemical class 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/06—Peri-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
- C07D221/12—Phenanthridines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
- C07D237/30—Phthalazines
- C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/93—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D475/00—Heterocyclic compounds containing pteridine ring systems
- C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US92252097A | 1997-09-03 | 1997-09-03 | |
US7950998A | 1998-05-15 | 1998-05-15 | |
US09/145,180 US20020022636A1 (en) | 1997-09-03 | 1998-09-01 | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
PCT/US1998/018195 WO1999011624A1 (fr) | 1997-09-03 | 1998-09-02 | Composes a substitution oxo, procede de fabrication associe, compositions les contenant, et methodes d'inhibition de l'activite de la poly(adenosine 5'-diphospho-ribose) polymerase |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20001002D0 NO20001002D0 (no) | 2000-02-28 |
NO20001002L true NO20001002L (no) | 2000-04-27 |
Family
ID=27373494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20001002A NO20001002L (no) | 1997-09-03 | 2000-02-28 | Oxo-substituerte forbindelser, fremgangsmõte for fremstilling, og sammensetninger og metoder for hemming av PARP aktiviteter |
Country Status (14)
Country | Link |
---|---|
US (2) | US20020022636A1 (fr) |
EP (1) | EP1009739A2 (fr) |
JP (1) | JP2002512637A (fr) |
KR (1) | KR20010023909A (fr) |
CN (1) | CN1278797A (fr) |
AU (1) | AU9298698A (fr) |
BR (1) | BR9812428A (fr) |
CA (1) | CA2294118A1 (fr) |
HU (1) | HUP0004693A3 (fr) |
IL (1) | IL134847A0 (fr) |
NO (1) | NO20001002L (fr) |
PL (1) | PL339082A1 (fr) |
TR (1) | TR200001557T2 (fr) |
WO (1) | WO1999011624A1 (fr) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6291425B1 (en) * | 1999-09-01 | 2001-09-18 | Guilford Pharmaceuticals Inc. | Compounds, methods and pharmaceutical compositions for treating cellular damage, such as neural or cardiovascular tissue damage |
AU9297998A (en) * | 1998-05-15 | 1999-12-06 | Guilford Pharmaceuticals Inc. | Carboxamide compounds, compositions, and methods for inhibiting parp activity |
ATE261963T1 (de) | 1999-01-11 | 2004-04-15 | Agouron Pharma | Tricyclische inhibitoren von poly(adp-ribose) polymerasen |
KR20010101675A (ko) * | 1999-01-26 | 2001-11-14 | 우에노 도시오 | 2h-프탈라진-1-온 유도체 및 그 유도체를 유효 성분으로하는 약제 |
JP2001002572A (ja) * | 1999-04-19 | 2001-01-09 | Sankyo Co Ltd | ニューロトロフィン作用増強剤 |
ECSP003637A (es) | 1999-08-31 | 2002-03-25 | Agouron Pharma | Inhibidores triciclicos de poli (adp-ribosa) polimerasas |
US6531464B1 (en) * | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
US6277990B1 (en) | 1999-12-07 | 2001-08-21 | Inotek Corporation | Substituted phenanthridinones and methods of use thereof |
US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
US6534651B2 (en) * | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
US7122679B2 (en) | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
US6723733B2 (en) * | 2000-05-19 | 2004-04-20 | Guilford Pharmaceuticals, Inc. | Sulfonamide and carbamide derivatives of 6(5H)phenanthridinones and their uses |
US6794383B2 (en) | 2000-08-31 | 2004-09-21 | Takeda Chemical Industries, Ltd. | Heart muscular cell apoptosis inhibitors and remedies/preventives for heart diseases |
US7151102B2 (en) | 2000-10-30 | 2006-12-19 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
JP4323802B2 (ja) | 2000-12-01 | 2009-09-02 | エムジーアイ・ジーピー・インコーポレーテッド | 化合物およびその使用 |
CA2330350A1 (fr) | 2000-12-05 | 2002-06-05 | Chemokine Therapeutics Corporation | Produits pour traiter des maladies a mediation chemokinique |
AU2002215737A1 (en) * | 2000-12-05 | 2002-06-18 | Chemokine Therapeutics Corporation | Tricyclic therapeutics for chemokine mediated diseases |
AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
DE60218458T2 (de) * | 2001-05-08 | 2007-11-15 | Kudos Pharmaceuticals Ltd. | Isochinolinon derivate als parp inhibitoren |
AUPS019702A0 (en) * | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
AUPS137402A0 (en) * | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
JP4500161B2 (ja) | 2002-04-30 | 2010-07-14 | クドス ファーマシューティカルズ リミテッド | フタラジノン誘導体 |
WO2004009556A1 (fr) * | 2002-07-24 | 2004-01-29 | Kyorin Pharmaceutical Co., Ltd. | Derive 4-(aryl substitue)-5-hydroxyisoquinolinone |
ES2380917T3 (es) * | 2002-10-01 | 2012-05-21 | Mitsubishi Tanabe Pharma Corporation | Compuestos de isoquinolina y su uso medicinal |
WO2004039859A1 (fr) | 2002-10-30 | 2004-05-13 | Sumitomo Chemical Company, Limited | Composes macromoleculaires et dispositifs polymeres electroluminescents fabriques au moyen de ces composes |
EP1566380B1 (fr) | 2002-11-22 | 2012-01-11 | Mitsubishi Tanabe Pharma Corporation | Composes d'isoquinolinone et leur utilisation a des fins medicinales |
GB0305681D0 (en) | 2003-03-12 | 2003-04-16 | Kudos Pharm Ltd | Phthalazinone derivatives |
US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
HU227948B1 (en) | 2003-04-30 | 2012-07-30 | Pecsi Tudomanyegyetem | Quinazoline derivatives and their use for the preparation of pharmaceutical compositions inhibiting parp enzyme |
US20050008699A1 (en) * | 2003-07-11 | 2005-01-13 | Fred Wehling | Effervescent glucosamine composition |
EP1687277B1 (fr) | 2003-11-20 | 2018-04-04 | Janssen Pharmaceutica NV | 2-quinolinones et 2-quinoxalinones substituees par 6-alcenyle et 6-phenylalkyle utilisees comme inhibiteurs de la poly(adp-ribose) polymerase (parp) |
UA89618C2 (ru) * | 2003-12-05 | 2010-02-25 | Янссен Фармацевтика Н.В. | 6-замещенные 2-хинолиноны и 2-хиноксалиноны как ингибиторы поли(адф-рибоза)полимеразы |
TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
DE102004028973A1 (de) * | 2004-06-16 | 2006-01-05 | Sanofi-Aventis Deutschland Gmbh | Substituierte Tetrahydro-2H-isochinolin-1-on-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
TWI389897B (zh) | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
GB0521373D0 (en) | 2005-10-20 | 2005-11-30 | Kudos Pharm Ltd | Pthalazinone derivatives |
EP1948215B1 (fr) | 2005-11-14 | 2012-01-11 | Centre National De La Recherche Scientifique (Cnrs) | Le domain non-histone de la MacroH2A comme inhibiteur d'activité PARP-1 et ses utilisations |
TWI417095B (zh) * | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途 |
AU2007289065B2 (en) | 2006-09-01 | 2013-03-14 | Senhwa Biosciences, Inc. | Serine-threonine protein kinase and PARP modulators |
TWI404716B (zh) | 2006-10-17 | 2013-08-11 | Kudos Pharm Ltd | 酞嗪酮(phthalazinone)衍生物 |
WO2008082887A2 (fr) * | 2006-12-28 | 2008-07-10 | Abbott Laboratories | Inhibiteurs de poly(adp-ribose)polymérase |
US9604931B2 (en) | 2007-01-22 | 2017-03-28 | Gtx, Inc. | Nuclear receptor binding agents |
EP2647376A1 (fr) * | 2007-01-22 | 2013-10-09 | Gtx, Inc. | Agents de liaison de récepteur nucléaire |
PL2118074T3 (pl) | 2007-02-01 | 2014-06-30 | Resverlogix Corp | Związki chemiczne do celów profilaktyki i leczenia chorób układu sercowo-naczyniowego |
TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
DK2134691T3 (da) | 2007-03-08 | 2012-05-07 | Janssen Pharmaceutica Nv | Quinolinonderivativer som parp- og tank-inhibitorer |
WO2008141081A1 (fr) * | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Tétrahydrobenzo-l,4-diazépines substituées par un aryle ou un hétéroaryle et utilisation desdites dans le blocage de la réassimilation de la norépinéphrine, de la dopamine et de la sérotonine |
US9114138B2 (en) | 2007-09-14 | 2015-08-25 | Janssen Pharmaceuticals, Inc. | 1′,3′-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2H,1′H-[1,4′] bipyridinyl-2′-ones |
TW200927731A (en) * | 2007-09-14 | 2009-07-01 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
AU2008299721A1 (en) | 2007-09-14 | 2009-03-19 | Astrazeneca Ab | Phthalazinone derivatives |
EA019085B1 (ru) | 2007-09-14 | 2014-01-30 | Янссен Фармасьютикалз, Инк. | 1',3-двузамещенные 4-(арил-х-фенил)-1н-пиридин-2-оны |
ES2448870T3 (es) * | 2007-10-26 | 2014-03-17 | Janssen Pharmaceutica, N.V. | Derivados de quinolina como inhibidores de PARP |
JP5433582B2 (ja) * | 2007-11-14 | 2014-03-05 | ジャンセン ファーマシューティカルズ, インコーポレイテッド. | イミダゾ[1,2−a]ピリジン誘導体およびmGluR2受容体の正のアロステリック調節因子としてのその使用 |
UY31603A1 (es) | 2008-01-23 | 2009-08-31 | Derivados de ftalazinona | |
WO2010025890A1 (fr) | 2008-09-02 | 2010-03-11 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc | Dérivés de 3-azabicyclo[3.1.0]hexyle comme modulateurs des récepteurs métabotropiques du glutamate |
CN102238945B (zh) | 2008-10-07 | 2014-10-29 | 阿斯利康(英国)有限公司 | 药物制剂514 |
EP2355660A4 (fr) * | 2008-10-13 | 2012-05-02 | Biovista Inc | Compositions et procédés pour traiter une sclérose en plaques |
AU2009304293B2 (en) | 2008-10-16 | 2012-04-26 | Addex Pharma S.A. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
BRPI0915273B1 (pt) * | 2008-11-11 | 2021-08-03 | Je Il Pharmaceutical Co., Ltd | Derivado tricíclico ou seus sais farmaceuticamente aceitáveis e seus métodos de preparação |
JPWO2010061908A1 (ja) | 2008-11-28 | 2012-04-26 | 中外製薬株式会社 | 1−(2h)−イソキノロン誘導体 |
AU2009319387B2 (en) | 2008-11-28 | 2012-05-10 | Addex Pharma S.A. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
US9238640B2 (en) | 2009-03-18 | 2016-01-19 | Resverlogix Corp. | Anti-inflammatory agents |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
CA2760259C (fr) | 2009-05-12 | 2018-05-01 | Janssen Pharmaceuticals, Inc. | Derives de la 1,2,4-triazolo [4,3-a] pyridine et leur utilisation en tant que modulateurs allosteriques positifs des recepteurs mglur2 |
JP5634506B2 (ja) | 2009-05-12 | 2014-12-03 | ジャンセン ファーマシューティカルズ, インコーポレイテッド | 1,2,3−トリアゾロ[4,3−a]ピリジン誘導体ならびに神経障害および精神障害の治療または予防のためのその使用 |
JP5852665B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
ES2552455T3 (es) | 2010-11-08 | 2015-11-30 | Janssen Pharmaceuticals, Inc. | Derivados de 1,2,4-triazolo[4,3-a]piridina y su uso como moduladores alostéricos positivos de receptores mGluR2 |
JP5852666B2 (ja) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4−トリアゾロ[4,3−a]ピリジン誘導体およびmGluR2受容体のポジティブアロステリックモジュレーターとしてのそれらの使用 |
US9227982B2 (en) | 2011-07-13 | 2016-01-05 | Novartis Ag | 4-oxo-3,5,7,8-tetrahydro-4H-pyrano[4,3-d]pyrminidinyl compounds for use as tankyrase inhibitors |
AU2012282076A1 (en) | 2011-07-13 | 2014-02-27 | Novartis Ag | 4 - piperidinyl compounds for use as tankyrase inhibitors |
WO2013012723A1 (fr) | 2011-07-13 | 2013-01-24 | Novartis Ag | Nouveaux composés 2-piperidin-1-yl-acetamide utilisables en tant qu'inhibiteurs de tankyrase |
JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
WO2015110435A1 (fr) | 2014-01-21 | 2015-07-30 | Janssen Pharmaceutica Nv | Combinaisons comprenant des modulateurs allostériques positifs ou des agonistes orthostériques de sous-type 2 de récepteur glutamatergique métabotrope, et leur utilisation |
LT3096790T (lt) | 2014-01-21 | 2019-10-10 | Janssen Pharmaceutica, N.V. | Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas |
CN114984016A (zh) | 2015-03-13 | 2022-09-02 | 雷斯韦洛吉克斯公司 | 用于治疗补体相关疾病之组合物及治疗方法 |
EP3263104A1 (fr) * | 2016-07-01 | 2018-01-03 | N-Gene Research Laboratories Inc. | Utilisation de bgp15 pour stimuler la fusion mitochondriale |
US10874641B2 (en) | 2016-07-28 | 2020-12-29 | Mitobridge, Inc. | Methods of treating acute kidney injury |
CN106798745A (zh) * | 2016-08-31 | 2017-06-06 | 四川省人民医院 | 一种用于治疗肿瘤疾病的药物 |
RU2019114863A (ru) | 2016-11-02 | 2020-12-03 | Иммуноджен, Инк. | Комбинированное лечение конъюгатами антитело-лекарственное средство и ингибиторами parp |
CN109293584B (zh) * | 2018-09-25 | 2021-11-26 | 暨南大学 | 靶向神经肽受体pac1-r的小分子别构调节化合物spam及其制备方法和用途 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US1880441A (en) * | 1932-10-04 | Etjbole m | ||
US3291801A (en) * | 1963-05-23 | 1966-12-13 | Grace W R & Co | Novel octahydro-6(5)-phenanthridinones and preparation thereof |
DE2355084A1 (de) * | 1972-11-06 | 1974-05-16 | Guidotti & C Spa Labor | Verbindungen mit magensaeuresekretionshemmender wirkung und verfahren zu deren herstellung |
US3932643A (en) * | 1974-01-07 | 1976-01-13 | Pfizer Inc. | Phenanthridines and phenanthridinones as antiviral agents |
SU514825A1 (ru) * | 1974-02-04 | 1976-05-25 | Химико-Фармацевтический Завод "Фармакон" | Способ получени хлоргидрата 1-фенил1-циклогексил-3-(1,-пиперидино) -пропанола-1 |
GB9404485D0 (en) * | 1994-03-09 | 1994-04-20 | Cancer Res Campaign Tech | Benzamide analogues |
US5589483A (en) * | 1994-12-21 | 1996-12-31 | Geron Corporation | Isoquinoline poly (ADP-ribose) polymerase inhibitors to treat skin diseases associated with cellular senescence |
-
1998
- 1998-09-01 US US09/145,180 patent/US20020022636A1/en not_active Abandoned
- 1998-09-02 KR KR1020007002595A patent/KR20010023909A/ko not_active Application Discontinuation
- 1998-09-02 CN CN98810936A patent/CN1278797A/zh active Pending
- 1998-09-02 EP EP98945833A patent/EP1009739A2/fr not_active Withdrawn
- 1998-09-02 HU HU0004693A patent/HUP0004693A3/hu unknown
- 1998-09-02 TR TR2000/01557T patent/TR200001557T2/xx unknown
- 1998-09-02 WO PCT/US1998/018195 patent/WO1999011624A1/fr not_active Application Discontinuation
- 1998-09-02 PL PL98339082A patent/PL339082A1/xx unknown
- 1998-09-02 JP JP51697799A patent/JP2002512637A/ja active Pending
- 1998-09-02 CA CA002294118A patent/CA2294118A1/fr not_active Abandoned
- 1998-09-02 AU AU92986/98A patent/AU9298698A/en not_active Abandoned
- 1998-09-02 BR BR9812428-5A patent/BR9812428A/pt not_active IP Right Cessation
- 1998-09-02 IL IL13484798A patent/IL134847A0/xx unknown
-
2000
- 2000-02-28 NO NO20001002A patent/NO20001002L/no not_active Application Discontinuation
-
2002
- 2002-04-01 US US10/109,730 patent/US20030105102A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1009739A2 (fr) | 2000-06-21 |
US20020022636A1 (en) | 2002-02-21 |
CN1278797A (zh) | 2001-01-03 |
CA2294118A1 (fr) | 1999-03-11 |
TR200001557T2 (tr) | 2001-01-22 |
HUP0004693A2 (hu) | 2001-10-28 |
AU9298698A (en) | 1999-03-22 |
US20030105102A1 (en) | 2003-06-05 |
BR9812428A (pt) | 2000-09-26 |
NO20001002D0 (no) | 2000-02-28 |
KR20010023909A (ko) | 2001-03-26 |
IL134847A0 (en) | 2001-05-20 |
HUP0004693A3 (en) | 2001-12-28 |
WO1999011624A1 (fr) | 1999-03-11 |
JP2002512637A (ja) | 2002-04-23 |
WO1999011624B1 (fr) | 1999-04-22 |
PL339082A1 (en) | 2000-12-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20001002L (no) | Oxo-substituerte forbindelser, fremgangsmõte for fremstilling, og sammensetninger og metoder for hemming av PARP aktiviteter | |
US20040176361A1 (en) | Fused heterocyclic compound and medicinal use thereof | |
MX9305379A (es) | Nuevos derivados de aminoacidos, procedimiento para su preparacion y preparado farmaceutico que los contiene. | |
NO304072B1 (no) | Dekahydroisoqinolin-forbindelser som er eksitatoriske aminosyre reseptorantagonister og farmasöytisk formulering derav | |
NO983749L (no) | CCR-3 reseptor-antagonister | |
NO20025641D0 (no) | Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister | |
ES2000185A6 (es) | Procedimiento para preparar derivados de acidos piridoncaboxilicos | |
YU53100A (sh) | Derivati 2-ariletil-(piperidin-4-ilmetil)amina kao antagonisti muskarinskih receptora | |
HUT57773A (en) | Process for produicng n-(aminocarbonyl)-carbamates related to physostigmine, as well as pharmaceutical compositions comprising such compounds | |
MY129176A (en) | Tetrahydro gamma-carbolines | |
MXPA04005426A (es) | Derivados de pirazol de anillos fuisionados. | |
MXPA04005076A (es) | Derivados de 4-piperidinil alquilamina como antagonistas del receptor muscarinico. | |
AR037459A1 (es) | Antagonistas vi del receptor ccr-3 | |
ES2380917T3 (es) | Compuestos de isoquinolina y su uso medicinal | |
BG105332A (en) | Tricyclic delta 3-piperidines as alpha2-antagonists | |
ATE48999T1 (de) | Piperazin-1-yl-ergolinderivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen. | |
NO973242L (no) | Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av idiopatisk eller fysiologisk gynekomasti | |
HUP0201321A2 (hu) | Új béta-amido- és béta-szulfonamido-karbonsavszármazékok, előállításuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
BG105331A (en) | BENZOTHIENO[3,4-c]PYRIDINES AS ALPHA2 ANTAGONISTS | |
ECSP951434A (es) | Nuevos derivados de aminoacidos, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos (ii) | |
ECSP961717A (es) | Nuevos derivados de arilglicinamida, procedimientos para su preparacion y composiciones farmaceuticas que contienen estos compuestos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |